Physician profile
Sally Monir Ibrahim
NPI 1215130786
$7,621.96
in general payments reported to CMS, 2019-2025
7 companies · $5,831 in 2025
The $5,831 reported for 2025 was more than what 94% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2022: $140 · 2023: $299 · 2024: $1,107 · 2025: $5,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,360 · Food and Beverage: $1,776 · Travel and Lodging: $911 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,360.00 |
| Food and Beverage | $1,776.24 |
| Travel and Lodging | $910.69 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $5,639.94 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $1,251.91 | 2019-2025 | |
| Inspire Medical Systems, INC. | $321.41 | 2019-2024 | Inspire |
| Harmony Biosciences LLC | $238.95 | 2023-2025 | Wakix |
| Abiomed | $136.52 | 2024 | Impella |
| Lilly USA, LLC | $16.73 | 2025 | Zepbound |
| Acadia Pharmaceuticals INC | $16.50 | 2023 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.